# Benralizumab Initiated During Severe Asthma Attack

> **NCT04617171** · PHASE2 · UNKNOWN · sponsor: **Singapore General Hospital** · enrollment: 128 (estimated)

## Conditions studied

- Asthma Attack
- Asthma

## Interventions

- **DRUG:** Benralizumab 30 MG/ML [Fasenra]
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04617171
- **Lead sponsor:** Singapore General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-02
- **Primary completion:** 2023-08
- **Final completion:** 2023-08
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2021-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04617171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04617171, "Benralizumab Initiated During Severe Asthma Attack". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04617171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*